ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsilocybin, a prodrug that converts to psilocin, exerts psychedelic and antidepressant effects primarily through serotonin 2A (5-HT
objectiveThis study aims to develop a physiologically based pharmacokinetic-pharmacodynamic (PBPK/PD) model to predict psilocin exposure, 5-HT
methodsA previously developed PBPK model that simulates psilocin plasma concentrations was coupled to two pharmacodynamic models. A maximum effect model was used to predict 5-HT
resultsThe model adequately predicted 5-HT
conclusionThis PBPK/PD framework links psilocin exposure to receptor engagement and clinical antidepressant response following psilocybin administration. The model may support dose selection and hypothesis generation for future clinical studies while also highlighting the need for more mechanistic models that integrate neuroplasticity and network-level processes.
Identifiers
42663926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.